Ozempic beyond weight loss: Separating science from hype

Beyond diabetes and obesity, GLP-1 drugs have now earned regulatory approval in several new areas. A trial of more than 17,000 people found semaglutide cut the risk of serious heart attacks and strokes by 20 per cent, even in people without diabetes.